Evidence map›Paper›PMID 26271717›Full record

ArticleBrain research2015

S-nitrosoglutathione reduces tau hyper-phosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion.

Je-Seong Won, Balasubramaniam Annamalai, Seungho Choi, Inderjit Singh, Avtar K Singh

Open access · bronzeAbstract read
In one paragraph

Article in Brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. The interaction between dysfunction of vasculature and tauopathy in Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Je-Seong WonDepartment of Pathology, Medical University of South Carolina, USA.
Balasubramaniam AnnamalaiDepartment of Pathology, Medical University of South Carolina, USA.
Seungho ChoiDepartment of Pediatrics, Medical University of South Carolina, USA.
Inderjit SinghDepartment of Pediatrics, Medical University of South Carolina, USA.
Avtar K SinghDepartment of Pathology, Medical University of South Carolina, USA; Pathology and Laboratory Medicine Service, Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA. Electronic address: avtar.singh@va.gov.
Medical University of South Carolina · US

Funding

CYTOKINES IN GLIAL CELLS AND EAE BRAINR01NS037766 · NINDS · UNIVERSITY OF NEVADA RENO · PI SINGH, INDERJIT · 1998 to 2019
$5.9M
Nitrosylation Mechanisms for Protection Against Neurovascular Inflammatory InjuryR01NS072511 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SINGH, AVTAR K · 2011 to 2015
$1.6M
Development of S-Nitrosothiol-based Therapy for Alzheimer's DiseaseI01BX001062 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI SINGH, AVTAR K · 2011 to 2014
–
Neuroprotection and Myelin Repair Mechanisms in Multiple SclerosisI01BX001072 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI SINGH, INDERJIT · 2011 to 2014
–
BLRD VA I01 BX001062BLRD VA I01 BX001072NINDS NIH HHS NS 037766NINDS NIH HHS NS072511NINDS NIH HHS R01 NS037766NINDS NIH HHS R01 NS072511
6 · The paper itself

Abstract

We have previously reported that treatment of rats subjected to permanent bilateral common carotid artery occlusion (pBCCAO), a model of chronic cerebral hypoperfusion (CCH), with S-nitrosoglutathione (GSNO), an endogenous nitric oxide carrier, improved cognitive functions and decreased amyloid-β accumulation in the brains. Since CCH has been implicated in tau hyperphosphorylation induced neurodegeneration, we investigated the role of GSNO in regulation of tau hyperphosphorylation in rat pBCCAO model. The rats subjected to pBCCAO had a significant increase in tau hyperphosphorylation with increased neuronal loss in hippocampal/cortical areas. GSNO treatment attenuated not only the tau hyperphosphorylation, but also the neurodegeneration in pBCCAO rat brains. The pBCCAO rat brains also showed increased activities of GSK-3β and Cdk5 (major tau kinases) and GSNO treatment significantly attenuated their activities. GSNO attenuated the increased calpain activities and calpain-mediated cleavage of p35 leading to production of p25 and aberrant Cdk5 activation. In in vitro studies using purified calpain protein, GSNO treatment inhibited calpain activities while 3-morpholinosydnonimine (a donor of peroxynitrite) treatment increased its activities, suggesting the opposing role of GSNO vs. peroxynitrite in regulation of calpain activities. In pBCCAO rat brains, GSNO treatment attenuated the expression of inducible nitric oxide synthase (iNOS) expression and also reduced the brain levels of nitro-tyrosine formation, thereby indicating the protective role of GSNO in iNOS/nitrosative-stress mediated calpain/tau pathologies under CCH conditions. Taken together with our previous report, these data support the therapeutic potential of GSNO, a biological NO carrier, as a neuro- and cognitive-protective agent under conditions of CCH.

Indexed as

Analysis of VarianceAnimalsBrainBrain IschemiaCalpainChronic DiseaseCyclin-Dependent Kinase 5Disease Models, AnimalGlycogen Synthase Kinase 3Neuroprotective AgentsPhosphorylationRatsS-NitrosoglutathioneSynaptosomestau ProteinsTyrosine3-nitrotyrosineCalpainCyclin-Dependent Kinase 5Glycogen Synthase Kinase 3Neuroprotective AgentsS-Nitrosoglutathionetau ProteinsTyrosineCalpainCdk5Chronic cerebral hypoperfusionp25, and tauS-nitrosoglutathione

Identifiers

PMID26271717
PMCPMC4630117
OpenAlexW1155260984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.